Posted by Michael Wonder on 10 Feb 2023
FDA approves Pfizer's supplemental new drug application for Cibinqo (abrocitinib)
10 February 2023 - Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to <18 years) with moderate to severe atopic dermatitis.
Pfizer announced today that the US FDA approved its supplemental new drug application for Cibinqo (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
